TNB-486
mAbexperimentalBi-specific
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Mar 2, 2021 (NCT04594642)
Timeline
Indications
Studied for
- Arthritis, Rheumatoid · Phase 1
- Hodgkin Disease · Phase 1
- Leukemia · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Lupus Erythematosus, Systemic · Phase 1
- Lymphoma, B-Cell · Phase 2
- Lymphoma, Follicular · Phase 3
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 3
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068301 ↗
- ChEMBLCHEMBL4650427 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07201558 | Phase 1 | Nov 28, 2025 | AstraZeneca |
| NCT07215585 | Phase 3 | Nov 2, 2025 | AstraZeneca, Peter MacCallum Cancer Centre |
| NCT06526793 | Phase 2 | Oct 28, 2024 | AstraZeneca |
| NCT06564038 | Phase 1/Phase 2 (Phase 2) | Sep 13, 2024 | AstraZeneca |
| NCT06549595 | Phase 3 | Aug 7, 2024 | AstraZeneca |
| NCT06137118 | Phase 1/Phase 2 (Phase 2) | Dec 26, 2023 | AstraZeneca |
| NCT04594642 | Phase 1 | Mar 2, 2021 | Teneobio, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 3 | 2023 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Teneobio, Inc. | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1